Its mechanism of action primarily involves inhibiting multiple angiogenesis and tumour proliferation-related signalling pathways, including: VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-β (PDGFR-β), RAF-1,c-Kit, and FMS-like tyrosine kinase 3 (Flt-3) (Yu et al., 2015). Here, FLT3 is linked to neoplasm.